Spectral Medical (TSE:EDT) Third Quarter 2024 Results

Key Financial Results

• Revenue: CA$502.0k (up 26% from 3Q 2023).

• Net loss: CA$10.00m (loss widened by 207% from 3Q 2023).

• CA$0.035 loss per share (further deteriorated from CA$0.012 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Spectral Medical Earnings Insights

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 58% growth forecast for the Biotechs industry in Canada.

Performance of the Canadian Biotechs industry.

The company's shares are down 5.1% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Spectral Medical (3 are potentially serious) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.